The earnings call reflects a positive trajectory for Stereotaxis with significant achievements like FDA approval for GenesisX and strong recurring revenue growth. However, financial losses and pending approvals are ongoing challenges.

Company Guidance

During Stereotaxis' Third Quarter 2025 Earnings Conference Call, CEO David Fischel provided guidance emphasizing significant developments and future expectations. The company anticipates exceeding $9 million in revenue for the fourth quarter, with a system revenue of approximately $3 million and recurring revenue surpassing $6 million, projecting over 20% annual growth for 2025. Looking ahead to 2026, Stereotaxis expects quarterly revenues to average above $10 million, driven by the GenesisX launch, which is anticipated to outpace Genesis orders post-launch. This is expected to be supported by an expanding portfolio of proprietary catheters, including MAGiC and MAGiC Sweep, which are already generating strong adoption, evidenced by $300,000 in MAGiC Sweep revenue within the first two months of its U.S. launch. The company is also focused on advancing its digital solutions, with the Synchrony and SynX systems expected to contribute significantly to revenue. Additionally, Stereotaxis is working towards U.S. approval for its MAGiC catheter, which could further enhance its market presence and revenue growth.

GenesisX FDA Approval

The GenesisX system received FDA approval, marking a significant milestone for Stereotaxis as it enhances their system opportunity by removing structural barriers and is expected to outpace the tempo of Genesis orders following full launch.

Growth in Recurring Revenue

Recurring revenue for the third quarter was $5.6 million, driven by increased adoption of MAGiC Sweep and Map-iT catheters, marking a significant increase from $4.8 million in the prior year.

Positive Reception of MAGiC Sweep

The MAGiC Sweep high-density mapping catheter achieved over $300,000 in revenue in its first two months of launch in the U.S., with only about 1/4 of robotic accounts ordering it so far.

Strong Financial Outlook for Q4 2025

Stereotaxis expects revenue this quarter to exceed $9 million, with system revenue of approximately $3 million and recurring revenue greater than $6 million, leading to over 20% annual revenue growth for the full year 2025.

Partnership with CardioFocus

Stereotaxis entered into a collaboration agreement with CardioFocus to enhance the compatibility of their PFA system with the MAGiC catheter, aiming for regulatory approval and commercialization.

Stereotaxis (STXS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

STXS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 27, 2026	2025 (Q4)	-0.06 / -	-0.09	―	―	―
Nov 11, 2025	2025 (Q3)	-0.06 / -0.07	-0.08	12.50% (<+0.01)	―
Aug 07, 2025	2025 (Q2)	-0.07 / -0.05	-0.07	28.57% (+0.02)	―
May 12, 2025	2025 (Q1)	-0.07 / -0.07	-0.06	-16.67% (-0.01)	―
Mar 03, 2025	2024 (Q4)	-0.07 / -0.09	-0.07	-28.57% (-0.02)	―
Nov 11, 2024	2024 (Q3)	-0.05 / -0.08	-0.07	-14.29% (>-0.01)	―
Aug 12, 2024	2024 (Q2)	-0.05 / -0.07	-0.07	0.00% (0.00)	―
May 13, 2024	2024 (Q1)	-0.06 / -0.06	-0.07	14.29% (+0.01)
Mar 04, 2024	2023 (Q4)	-0.07 / -0.07	-0.06	-16.67% (-0.01)	―
Nov 09, 2023	2023 (Q3)	-0.06 / -0.07	-0.07	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

STXS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 11, 2025	$2.85	$2.43	-14.74%
Aug 07, 2025	$2.19	$2.50	+14.16%
May 12, 2025	$2.07	$2.11	+1.93%
Mar 03, 2025	$2.06	$1.94	-5.83%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Stereotaxis (STXS) report earnings?

Stereotaxis (STXS) is schdueled to report earning on Feb 27, 2026, Before Open (Confirmed).

What is Stereotaxis (STXS) earnings time?

Stereotaxis (STXS) earnings time is at Feb 27, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is STXS EPS forecast?

STXS EPS forecast for the fiscal quarter 2025 (Q4) is -0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing